李环球

发布者:金雪明发布时间:2018-11-04浏览次数:7652



姓  名:李环球

职称职务:副教授,硕士生导师

电子邮箱:huanqiuli@suda.edu.cn

办公地址:云轩楼1324


个人简介:

一、学习工作经历

1、学历背景:

2004.92008.9南京大学生命科学院,硕博连读,理学博士

2000.92004.7吉林大学生物与农业工程学院,工学学士

2、工作经历:

2014.32015.5美国新墨西哥大学化学与化学生物系,访问学者

2011.3- 今www.优德88.cpm 医学部药学院,副教授

2008.9 -2010.12南京大学化学化工学院,博士后

二、研究方向

1)基于嘌呤受体信号的抗炎免疫药物研发

2)肿瘤免疫治疗药物研发

3)人工智能药物

三、主要成绩及研究成果

主要从事药物化学与化学生物学的研究,集中在免疫炎症和肿瘤免疫治疗新靶标的发现及新药研发,先后参与十四五国家重点研发计划一项,主持国家自然科学基金2项、江苏省自然科学基金等省部级项目3项、国家博士后项目2项,市厅级及企事业横向合作项目6项。以第一作者或通讯作者在Eur Heart JNat CommunJ Adv ResCell Death DisJ Med ChemEur J Med ChemPhytomedicineDrug Discov Today等中科院一区TOP期刊发表科研论文60余篇;申请国际及国家发明专利17项,获授权12项,其中一项抗痛风新药专利(CN201811507809.8)以2000万的金额成功转化。以第二完成人获得教育部自然科学技术二等奖一项,湖南省自然科学三等奖一项。曾指导学生获得2021中国国际互联网+创新创业大赛铜奖,2022年江苏省优秀硕士学位论文。

近三年发表论文

    1. Chunxiao Liu, Hui Wang, Lu Han, Yifan Zhu, Shurui Ni, Jingke Zhi, XipingYang, Jiayi Zhi, Sheng Tian,Huanqiu Li*, Qinghua Hu*. Targeting P2Y14R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis.Nat Commun2024, 15:2083.一区top期刊IF:16.6

    2. Yehong Li† , Mengze Zhou†,Huanqiu Li†, Chen Dai† , Li Yin, Chunxiao Liu, Yuxin Li, Enming Zhang, Xinli Dong, Hui Ji, Qinghua Hu. Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways.Eur Heart J2024, 45, 268–283.一区top期刊IF:38.8

    3. Zhu YF,Zhou MZ,Cheng XY,Wang H,Li YH,Guo YY,Wang YX,Tian S,Mao TQ,Zhang ZD,Li DX,Hu QH*,Li HQ*. Discovery of Selective P2Y6R Antagonists with High-Affinity and In Vivo Efficacy for Inflammatory Diseases Therapy.J Med Chem.2023,66, 6315-6332.一区top期刊IF:7.8

    4. Li YX, Li YH, Zhu YF, Ji W, Wang YX, Dong XL, Zhao X, Wang T, Tian S, Hu QH,Li HQ*, Zhou MZ.Structure-based virtual screening for discovery of paederosidic acid from Paederia scandens as novel P2Y14R antagonist.Phytomedicine.2023, 115, 154851.I一区top期刊IF:7.9

    5. Wang MM, Zhang ZD, Chen MX, Lv YX, Tian S, Meng FY, Zhang YW, Guo XQ, Chen Y, Yang M, Li JW, Qiu T, Xu F, Li Z, Zhang Q, Yang J, Sun J, Zhang HJ, Zhang HY,Li HQ*Wang WP*.FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer.Cell Death Dis2023,14(8): 495.一区top期刊IF:9.8

    6. Zhou M, Wang W, Wang Z, Wang Y, Zhu Y, Lin Z, Tian S, Huang Y, Hu Q*,Li H*. Discovery and computational studies of 2-phenyl-benzoxazole acetamide derivatives as promising P2Y14R antagonists with anti-gout potential.Eur J Med Chem227: 113933 (2022).一区top期刊IF:7.08

    7. Zhu YF, Wang H, Guo YY, Cao J,Li HQ*Advances in the Therapeutic Potential of Inhibitors Targeting Glycogen Synthase Kinase 3 in Inflammatory Diseases.Mini-Rev Med Chem2023, 23,1893-1904.

    8. Jiayi Zhi, Li Yin, Zhoudong Zhang, Yaozhong Lv, Fan Wu, Yang Yang, Enming Zhang,Huanqiu Li,*Ning Lu, Mengze Zhou *, Qinghua Hu. Network pharmacology-based analysis of Jin-Si-Wei on the treatment of Alzheimers disease. J Ethnopharmacol2024, 319,117291. IF = 5.9

    9. Lv Y, Zhang Z, Tian S, Wang W,Li HQ*. Advances in the therapeutic potential of inhibitors targeting fucosyltransferases in cancer.Drug Discov Today2023, 28, 103394.IF:8.3

    10. Lv Y, Tian S, Zhang Z, Feng T,Li H*. LSD1 inhibitors for anticancer therapy: a patent review (2017-present).Expert Opin Ther Patents.2022,32, 1027-1042.

    11. Song J, Wang J, Tian S,Li H*. Discovery of STAT3 Inhibitors: Recent Advances and Future Perspective.Curr Med Chem2023, 30, 1824-1847

    12. Zhang Y, Wang M, Meng F, Yang M, Chen Y, Guo X, Wang W, Zhu Y, Guo Y, Feng C, Tian S, Zhang H,Li H*, Wang W*. A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis.Cell Death Discov8 (1): 238 (2022). IF:7.10

    13. Liu C, Zhou M, Jiang W, Ye S, Tian S, Jiang C, Hao K,Li H*, Hu Q*. GPR105-Targeted therapy promotes gout resolution as a switch between NETosis and apoptosis of neutrophils.Front Immunol13: 870183 (2022).IF:8.78

    14. Wang W, Liu C, Li H, Tian S, Liu Y, Wang N, Yan D,Li H*, Hu Q*. Discovery of novel and potent P2Y14R antagonists via structure-based virtual screening for the treatment of acute gouty arthritis.J Adv Res23: 133-142 (2020). IF:12.82

    15. Zhou M, Wang W, Li Y, Zhang Q, Ji H,Li H*, Hu Q*.The role of P2Y6R in cardiovascular diseases and recent development of P2Y6R antagonists, Drug Discov Today (2020) 25(3): 568-573. IF:8.36

      纵向科研项目

  1. 国家自然科学基金面上项目,82373725,新型抗动脉粥样硬化P2Y6R选择性抑制剂的设计、优化及作用机制研究,2024/01-2027/1249万,在研,主持

  2. 苏州市科技计划,医疗卫生科技创新, SKY2022103, FUT8作为转移型结直肠癌治疗靶标的确证及小分子靶向药物的研发, 2022/07-2025/06, 5万元,在研,主持

  3. 国家自然科学基金面上项目,81773745P2Y14R对急性痛风性关节炎的调控作用及先导化合物的靶向干预机制研究,2018/01-2021/1261.5万,合作主持,已结题。

  4. 江苏省自然科学基金面上项目,BK20181437, XOD-NLRP3双重抑制剂的设计合成及其作为痛风治疗药物的研究,2018/01-2021/12, 10万,主持。

  5. 苏州市科技计划医疗卫生基础研究项目,SYS201665,新型治疗急性痛风性关节炎药物的设计、合成及其活性研究,2016/07-2019/06, 3万元,主持。

  6. 国家自然科学面上项目,81273372,腺苷受体A2A拮抗剂作为治疗帕金森综合症新型药物的可行性研究,2013/01-2016/1265万元,第二执行人